Alterity Therapeutics Ltd. · ASX:ATH

Alterity Therapeutics — Prana Biotechnology — J.P. Morgan Healthcare Conference 2018

23 slides from Alterity Therapeutics's conference presentation, January 2018

  1. Slide 1: Treatment of Neurological Disorders

    Treatment of Neurological Disorders David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018 1

  2. Slide 2: Corporate Overview

    Corporate Overview • Developing first-in-class therapies to treat orphan and non-orphan neurological diseases. Trading information: ASX: PBT • Lead program, PBT434, is the first of a new generation of small Nasdaq: PRAN molecules designed to block iron-mediated accumulation and Share price: US$3.23

  3. Slide 3: An International Business

    An International Business Listed on Nasdaq in 2000 (PRAN) San Francisco, USA • Clinical Development team Established in 1997 in Australia, listed on ASX (PBT) Melbourne, Australia • Headquarters • Discovery and Research team 3

  4. Slide 4: Investment Highlights

    Investment Highlights Novel Drug Candidate: PBT434 • Targets key proteins implicated in the neurodegeneration of Parkinson’s disease and atypical parkinsonism • Prevents accumulation of α-synuclein and tau • Well tolerated in repeated dose toxicology studies Strong Research and Development • Innovat

  5. Slide 5: Management Team

    Management Team Geoffrey Kempler, Executive Chairman & CEO David Stamler, MD, Chief Medical Officer & SVP Development • Founded Prana in November 1997 • Extensive experience in investment and • Previous VP, Clinical Development and Therapeutic business development Head, Movement Disorders, Teva Phar

  6. Slide 6: Investment Thesis

    Investment Thesis • Alpha (α)-synuclein is a soluble, intracellular protein critical for neuro transmission • Alpha-synulein accumulates and aggregates in many neurodegenerative diseases, implicated in pathology • PBT434 blocks α-synuclein accumulation and aggregation, preserves neurons and improves

  7. Slide 7: PBT434: Promising Drug Profile

    PBT434: Promising Drug Profile • Good CNS penetration based on low molecular weight and lipophilicity • Concentrates in brain 2 to 3 fold higher than plasma • Straightforward synthetic process with demonstrated ability to make kg amounts of GMP material • Benign safety profile in GLP toxicology stud

  8. Slide 8: Importance of α-Synuclein

    Importance of α-Synuclein • α-Synuclein is an intracellular protein, abundantly expressed in the brain • Critical for normal function of neurons • Soluble, in highest concentration at presynaptic nerve endings • Key regulatory protein involved in neurotransmission • Enables neurotransmitter release

  9. Slide 9: α-Synuclein is an Important Disease Target

    α-Synuclein is an Important Disease Target Strong genetic and pathological link to disease “Collectively these data strongly suggest that alpha synuclein is a potentially important and novel target of candidate neuroprotective therapies. Several different therapeutic strategies designed to clear or

  10. Slide 10: PBT434 Inhibits α-Synuclein Accumulation and Aggregation

    PBT434 Inhibits α-Synuclein Accumulation and Aggregation • α-synuclein fibrillizes in vivo; only form of synuclein to fibrillize in vitro • Factors regulating α- αSN+Fe synuclein production and conformation are relevant to disease pathogenesis and treatment • Homeostasis of iron is disrupted in PD a

  11. Slide 11: Alpha-synuclein Pathology and PBT434 Mechanism of Action

    Alpha-synuclein Pathology and PBT434 Mechanism of Action Iron Chaperone, reducing α-synuclein accumulation, aggregation and preserving neurons Cell Death Fe Fe OH• Fe2+ Fe2+ Accumulation Fe Fe Fe Fe2+ Fe2+ Fe Fe Fe Fe H2O2 Fe Fe Fe Fe Fe Fe Fe Fe Fe Fe Fe Fe Cytoplasm Extracellular Ferroportin ↑ Fe3

  12. Slide 12: PBT434 Target Product Profile

    PBT434 Target Product Profile Mechanism of Action Inhibitor of iron-mediated protein accumulation and aggregation By inhibiting accumulation and aggregation of α-synuclein, PBT434 preserves Product Concept neurons and improves motor and non-motor symptoms of neurodegenerative diseases Potential Indi

  13. Slide 13: PBT434 Lowers α-Synuclein, Prevents Neuronal Death and Improves Motor Function

    PBT434 Lowers α-Synuclein, Prevents Neuronal Death and Improves Motor Function Transgenic Animal Model (hA53T) of Parkinson’s Disease ↓ α-Synuclein aggregation Preserves neurons in S. nigra Foot Clasping * * 6 8 0 0 0 1 0 0 * * s * * n n o y 4 r - s g u i n e  n p T s c 3 4 0 0 0 5 0 l a p 5 N C 2

  14. Slide 14: Strategy Supported by Proof of Concept with Deferiprone

    Strategy Supported by Proof of Concept with Deferiprone 6 month placebo controlled data in Parkinson’s disease patients Brain Iron by MRI Motor Function – UPDRS III Deferiprone • Indicated for Treatment of Iron Overload Worsening • Black Box for neutropenia and agranucloctyosis • Iron Binding Affini

  15. Slide 15: Link Between Iron and Severity of PD

    Link Between Iron and Severity of PD Gotz et al. Ann N.Y. Acad Sci. 2004 However, biochemical studies have reported increased iron content in the nigra in PD,2-4 with the changes most marked in severe disease (PD)5 Martin, et al. Neurology 2008;70:1411–1417 CONFIDENTIAL 15

  16. Slide 16: Brain Iron Increased in Parkinson's Disease Patients

    Brain Iron Increased in Parkinson’s Disease Patients n=7 Substantia nigra (T) n = 9 * Patients And in Multiple System Atrophy Patients Controls n=8 * Substantia nigra (pc) n = 3 n=8 n = 13 Cerebral cortex n = 11 Cerebellum n = 24 n=8 * 0 10000 20000 30000 Caudate nucleus n = 10 nmol iron/g of human

  17. Slide 17: Multiple System Atrophy

    Multiple System Atrophy • Progressive neurodegenerative disorder leading to severe disability and impairment in quality of life • Sporadic, typically presents in 50s to 60s • Orphan Indication: Prevalence ~5 per 100,000 in the U.S. • Characterized by a variable combination of • Parkinsonism, which r

  18. Slide 18: PBT434 Lowers α-Synuclein, Prevents Neuronal Death and Improves Function

    PBT434 Lowers α-Synuclein, Prevents Neuronal Death and Improves Function Transgenic Animal Model of MSA [(PLP)-α-SYN] of Multiple System Atrophy Preliminary Data ↓ α-Synuclein aggregation Neurons in S. nigra Rotarod Test 6 0 0 0 0 . 1 5 p = 0 . 0 7 9 * * * 3 0 * i t s n s u n e r o c 4 0 0 0 ) 0 . 1

  19. Slide 19: Structure and Function of Tau

    Structure and Function of Tau PBT434 Prevents Abnormal Tau Accumulation • Tau is an intracellular protein expressed in neurons and glial support cells • Natively unfolded, highly soluble protein • Primary role is to regulate and stabilize microtubules inside cells, which is critical to normal cellul

  20. Slide 20: Brain Iron is also Increased in Tauopathies

    Brain Iron is also Increased in Tauopathies E.g.: Progressive Supranuclear Palsy n = 11 Cerebral cortex n = 13 Patients n = 11 Caudate nucleus n = 14 Controls n = 11 * Putamen (T) n = 13 n=7 * Substantia nigra (T) n=8 n=7 Cerebellum n = 12 0 10000 20000 30000 nmol iron/g of human brain Dexter et al.

  21. Slide 21: PBT434 demonstrated highly significant improvement in the Y-maze cognitive assessment

    PBT434 demonstrated highly significant improvement in the Y-maze cognitive assessment Transgenic Animal Model of Tauopathy (rTg4510) Tau accumulation in hippocampus Performance in Y-maze * 0 . 2 5 4 0 * r m a r e 0 . 2 0 a l 3 5 / a e e v i t i v o 0 . 1 5 N s 3 0 i n o p 0 . 1 0 ) ( % 1 I 5 2 5 e M

  22. Slide 22: PBT434 has Potential for Wide Application in Neurodegenerative diseases

    PBT434 has Potential for Wide Application in Neurodegenerative diseases α-Synuclein and Tau proteins Share Pathogenic Features Parameter α-Synuclein Tau Localization Intracellular Intracellular Native form Soluble Soluble Physiologic function Facilitates synaptic function Microtubule assembly and st

  23. Slide 23: Development Milestones

    Development Milestones • GMP Manufacturing 1Q ‘18 • Phase 1 (SAD/MAD) start mid ‘18 • Initiate LT Toxicology 2H ‘18 • New IND 2H ‘19 • Phase 2 start 1H ‘20 CONFIDENTIAL 23

Prana Biotechnology — J.P. Morgan Healthcare Conference 2018 on 6ix